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ABSTRACT
Following peripheral nerve injury microglia accumulate
within the spinal cord and adopt a proinﬂammatory pheno-
type a process which contributes to the development of neu-
ropathic pain. We have recently shown that neuregulin-1, a
growth factor released following nerve injury, activates
erbB 2, 3, and 4 receptors on microglia and stimulates pro-
liferation, survival and chemotaxis of these cells. Here we
studied the intracellular signaling pathways downstream of
neuregulin-1-erbB activation in microglial cells. We found
that neuregulin-1 in vitro induced phosphorylation of
ERK1/2 and Akt without activating p38MAPK. Using spe-
ciﬁc kinase inhibitors we found that the mitogenic effect of
neuregulin-1 on microglia was dependant on MEK/ERK1/2
pathway, the chemotactic effect was dependant on PI3K/
Akt signaling and survival was dependant on both path-
ways. Intrathecal treatment with neuregulin-1 was associ-
ated with microgliosis and development of mechanical and
cold pain related hypersensitivity which was dependant on
ERK1/2 phosphorylation in microglia. Spinal nerve ligation
results in a robust microgliosis and sustained ERK1/2 phos-
phorylation within these cells. This pathway is downstream
of neuregulin-1/erbB signaling since its blockade resulted
in a signiﬁcant reduction in microglial ERK1/2 phosphoryl-
ation. Inhibition of the MEK/ERK1/2 pathway resulted in
decreased spinal microgliosis and in reduced mechanical
and cold hypersensitivity after peripheral nerve damage.
We conclude that neuregulin-1 released after nerve injury
activates microglial erbB receptors which consequently
stimulates the MEK/ERK1/2 pathway that drives microglial
proliferation and contributes to the development of neuro-
pathic pain. V V C 2011 Wiley-Liss, Inc.
INTRODUCTION
Microglial cells are the resident immune cells of the
central nervous system. They display remarkable plas-
ticity and can change their physiology in response to
environmental cues. Following injury they proliferate
and migrate to accumulate in regions of neuronal degen-
eration and produce a wide variety of pro-inﬂammatory
molecules (reviewed in Inoue and Tsuda, 2009; Scholz
and Woolf, 2007). Production of such pro-inﬂammatory
substances including IL-1b, TNF-a, NO, BDNF, or IL-6,
can further recruit microglia, activate astrocytes, and
increase neuronal excitability (reviewed in Milligan and
Watkins, 2009). Injury to a peripheral nerve results in a
marked microgliosis within the dorsal horn of the spinal
cord and this contributes to the development of neuro-
pathic pain (Tsuda et al., 2003). In such situations
where the blood brain barrier is not disrupted (Abram
et al., 2006; Lu et al., 2009) proliferation and migration
of resident microglia is likely to be the principal means
by which microglial numbers increase (Ajami et al.,
2007). Therefore signals within microglia that enhance
microglial proliferation and chemotaxis appear as poten-
tial targets to modulate the excessive inﬂammatory
response and potentially the development of neuropathic
pain. Neuregulin 1 (NRG1)-erbB signaling has recently
been identiﬁed as one such target (Calvo et al., 2010).
NRG1 is one of a family of growth factors (NRG1-4)
which has a key role in neural and cardiac development
(Gassmann et al., 1995; Lee et al., 1995; Meyer and
Birchmeier, 1995), it can modulate synaptic plasticity
(reviewed in Mei and Xiong, 2008) and stimulate the
proliferation, survival and motility of a number of differ-
ent cell types. We have recently shown that NRG1 is a
survival, proliferative and chemotactic factor for micro-
glia in vitro and in addition can promote the release of
Il-1b from these cells. Treatment in vivo with intra-
thecal NRG1 induces cold and mechanical pain related
hypersensitivity (Calvo et al., 2010; Lacroix-Fralish
et al., 2008). Peripheral nerve injury results in the acti-
vation of NRG1-erbB signaling speciﬁcally within micro-
glia contributing to the development of microgliosis and
consequently neuropathic pain (Calvo et al., 2010).
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V V C 2011 Wiley-Liss, Inc.Through alternative splicing, the NRG1 gene produces
numerous isoforms which include both secreted and
transmembrane forms (which can undergo further
proteolytic processing to be released from the cell
membrane, (reviewed in Esper et al., 2006; Newbern
and Birchmeier, 2010). All isoforms have an EGF-like
domain that is critical for mediating biologic activity
and which binds to the tyrosine kinase receptors erbB3
and 4. These receptors, subsequently heterodimerize
with erbB2 which lacks a ligand binding domain but
which is a key co-receptor in mediating signal transduc-
tion (Carraway and Cantley, 1994). Within an activated
receptor dimer, the C-terminal regulatory tail is trans-
autophosphorylated on tyrosines and recruits down-
stream signaling molecules that contain phosphotyro-
sine-binding Src homology-2 (SH2) domains. Intracellu-
lar signaling pathways which have been demonstrated
to be subsequently activated include the extracelullar
signal regulated kinases (ERK), the p38 mitogen-
activated protein kinases (p38 MAPK), and the phospha-
tidylinositol-3-kinase (PI3K)/Akt pathway. These can
modulate distinct aspects of the cellular response for
instance ERK signaling promotes cell proliferation
and PI3K/Akt cellular motility (Eckert et al., 2009;
Maurel and Salzer, 2000; Sei et al., 2007) in response to
NRG1.
Microglia express all three erbB 2, 3, and 4 receptors
(Calvo et al., 2010; Dimayuga et al., 2003; Gerecke
et al., 2001). The intracellular signaling cascades down-
stream of NRG1-erbB signaling within these cells are
however unknown. Both the ERK and p38 MAPK path-
ways have previously been shown to be activated
within microglia of the dorsal horn following peripheral
nerve injury (reviewed in Ji et al., 2009) making them
interesting candidates for mediating NRG1 effects.
Here we demonstrate that NRG1 which is released af-
ter nerve injury and signals via the erbB receptors
activates the mitogen-activated ERK-regulating kinase
(MEK)/ERK pathway in microglia. This leads to an
increase in proliferation of these cells and a proinﬂam-
matory phenotype that induces the development of
neuropathic pain.
MATERIALS AND METHODS
Animals and Surgery
Adult male Wistar rats were used in accordance with
UK Home Ofﬁce regulations. Nerve injury was produced
by tight ligation and transection of the left L5 spinal
nerve. Brieﬂy, animals were anaesthetized using a mix-
ture of medetomidine hydrochloride (0.25 mg/kg) and ke-
tamine (60 mg/kg) administered in a single intra-perito-
neal injection. The animals were placed in the prone
position and under sterile conditions a paramedial inci-
sion was made to access the left L4-L6 spinal nerves.
Approximately one-third of the L6 transverse process
was removed. The L5 spinal nerve was identiﬁed and
carefully dissected free from the adjacent L4 spinal
nerve and then tightly ligated using 6-0 silk and then
transected distally to the suture. The muscle layer was
sutured, and the wound was closed with Vicryl 3-0. To
label dividing cells, rats were injected with 5-bromo-20-
deoxyuridine (BrdU; Sigma dissolved in 0.007N NaOH/
PBS, 100 mg/kg body weight i.p.) 24 hours before perfu-
sion and ﬁxation.
Intrathecal Injections
Injections were performed by lumbar puncture using
the method described by Mestre et al. (1994). Under
isoﬂuorane anaesthesia a 26G needle from an insulin
syringe (Myjector U-100 Terumo) was inserted between
the L5 and L6 vertebrae, where the cord consists mainly
of spinal roots. A volume of 10 or 20 lL was injected at
a constant speed after which the needle was slowly
removed. The quality of each injection was ensured by
the observation of an injection-induced tail-ﬂick.
Drugs and Delivery
Neuregulin b1 EGF domain (rHRGb1 aa176-246,
R&D Systems cat no. 396HB) was intrathecally adminis-
tered at 0.4 or 4 ng dissolved in sterile saline in a vol-
ume of 20 lL. Injections were repeated every 24 hours
and the animals were sacriﬁced at day 4. In another
experiment NRG1 was administered to naive animals
together with the MEK inhibitor U0126 (Promega) or
the inactive analogue U0124 (Merck) which were dis-
solved in 24% DMSO and saline (as previously described
by Zhuang et al., 2005). For this experiment a syringe
was ﬁlled with 10 lL of inhibitor or the inactive
analogue (10 lg) and 10 lL of NRG1 (4 ng) which were
separated by a small air bubble. The injections were per-
formed once daily four times. Behavioral tests were done
24 hours after each injection for the ﬁrst 3 days, and the
animals were sacriﬁced at day 4. In other experiments
we administered U0126 or U0124 (10 lgi n2 0lL) daily
through lumbar punctures to animals which underwent
a L5 spinal nerve ligation.
For continuous intrathecal delivery of the erbB2
inhibitor PD168393 we inserted an intrathecal catheter
that was connected to an Alzet osmotic pump (Cuper-
tino, model 2002) ﬁlled with the inhibitor. Brieﬂy, a
laminectomy of the L2 vertebra was performed, the dura
was cut and a soft catheter was inserted into the subar-
achnoid space of the spinal cord. PD 168393 (Calbio-
chem) an irreversible erbB inhibitor was dissolved in 5%
DMSO and delivered intrathecally at 10 lg/day. Control
animals were given the same vehicle solution lacking
the active compound. To sequester endogenous NRG1,
we used a fusion protein (HBD-S-H4, Ma et al., 2009)
that was injected intrathecally once at the time of sur-
gery (3 lgi n2 0lL of sterile saline per injection).
The drug doses were selected on the basis of previous
reports and our preliminary studies. Before surgery ani-
mals were randomly allocated into experimental study
groups (computer-generated randomization schedules).
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Behavioral Testing
Mechanical withdrawal thresholds were tested using a
Dynamic Plantar Aesthesiometer (Ugo Basile, Italy)
which is an automated version of the von Frey hair
assessment. A maximum cut-off of 50 g was used. The
withdrawal threshold is calculated as the average of
three consecutive tests with at least 10 min between
each test. To measure cold allodynia, we applied a drop
of acetone to the plantar hindpaw and measured the
time that the animal spent licking, shaking, or lifting
the paw during the following 2 min (Kontinen and Dick-
enson, 2000). All behavioral tests were performed by an
investigator blinded to randomization schedule.
Histology
After deﬁned survival times, animals were terminally
anaesthetized and transcardially perfused with 4% para-
formaldehyde plus 1.5% picric acid in 0.1M phosphate
buffer. The lumbar spinal cords were excised, cryopro-
tected in 20% sucrose, cryostat cut (20 lm) and thaw-
mounted onto glass slides. Spinal cord sections were
incubated overnight with the primary antibody: rabbit
anti-phospho-p38MAPK (1:100, Cell Signalling), rabbit
anti-phosphoAkt (1:100, Cell Signalling) or rabbit anti-
phospho-ERK (1:500, Cell Signalling), all of which were
viewed by tyramide ampliﬁcation (TSA
TM Biotin System,
Perkin Elmer) For co-localization studies the slides were
then incubated with rabbit anti-Iba1 (1:1,000, WAKO).
Following primary antibody incubation sections were
washed and incubated for 1.5 hours with corresponding
secondary antibody solution (Extra-Avidin FITC 1:500 or
Cy3 1:400, both from Stratech, UK). Slides were washed,
cover-slipped with Vectashield mounting medium (Vector
Laboratories) and visualised under a Zeiss Axioplan 2
ﬂuorescent microscope (Zeiss, UK). Antibody detection of
BrdU incorporated into DNA requires pre-treatment of
the tissue to expose the BrdU epitope. For this purpose
we used the antigen retrieval method described previ-
ously (Tang et al., 2007). Primary antibody solution con-
tained mouse anti BrdU (1:200, BD:Biosciences) plus
rabbit anti Iba-1 (1:1,000, Wako) and the Secondary
Antibody solution contained corresponding IgG-conju-
gated FITC 1:200 plus IgG-conjugated Cy3 1:400 (both
from Stratech, UK). Microglia cells were 4% PFA ﬁxed
for immunohistochemistry. Microglia were identify using
Iba1 antibody (1:1,000, WAKO). Proliferation in micro-
glial cells was assessed using BrdU 10 lM which was
administered 15 hours before ﬁxation. Antigen retrieval
was achieved by denaturing DNA with 2N HCl incuba-
tion for 30 min at 37C, and neutralizing the acid by
immersing sections in 0.1M borate buffer (pH 8.5) for 10
min. Cells were then ready for staining using the same
protocol previously described.
Primary Microglia Cell Culture
Mixed glial cultures were isolated from cortex of P3
Wistar rats according to the method of Giulian and
Baker (Giulian and Baker, 1986). After mechanical and
chemical dissociation cells were seeded in DMEM with
10% FBS at a density of 500,000 cells/mL and cultured
at 37C in humidiﬁed 5% CO2/95% air. All reagents used
were purchased from Invitrogen. Medium was replaced
every 2 to 3 days and conﬂuency was achieved after 5
days in vitro. Conﬂuent mixed glial cultures were man-
ually shaken for 5 min and the ﬂoating cells were pel-
leted and subcultured. This method resulted in 96% to
99% purity as assessed by Iba1 and DAPI staining. Cells
were incubated overnight in standard medium to allow
them to attach ﬁrmly to the coverslips. The next day
they were incubated in serum free medium for 2 to 4
hours to ensure these cells were in a resting or basal
condition before using them for experiments. Neuregulin
b1 EGF domain (rHRGb1 R&D Systems) was used
(10 nM) for survival, proliferation and chemotaxis
assays. Each assay consisted in at least three independ-
ent experiments each of which had every condition
applied in triplicates. For survival assays microglial cells
were suspended in serum-free DMEM and treated with
the PI3K inhibitor Wortmannin (1 lM, Sigma) or the
MEK inhibitor U0126 (10 lM, Promega) or 0.1%DMSO
(vehicle) alone or with NRG1 10 nM and left for 3 days
before ﬁxation and staining. For proliferation assays
microglial cells were suspended in 5% FBS DMEM and
treated in the same way.
Chemotaxis Assay
Chemotaxis was assessed using the Boyden chamber
(Neuroprobe, Bethesda, MD). Polycarbonate ﬁlters (5 lm
pore) were installed in the chamber, whose bottom wells
were ﬁlled with serum-free DMEM with or without
NRG1 (10 nM). Freshly prepared microglia were sus-
pended in serum-free DMEM and were pre-treated for
1 hour with the different kinase inhibitors (Wortmannin
1 lM or U0126 10 lM or 0.1%DMSO). Then they were
placed into the top wells (50,000 cells/well) of the Boy-
den chamber and left in a CO2 incubator at 37C for
3 hours. The ﬁlter was removed; the cells on the top
side of the ﬁlter were wiped off and the ﬁlter with the
remaining migrated cells was ﬁxed with Methanol for
10 min and stained with RapiDiffII (Biostain RRL, UK).
Photomicrographs were acquired under light microscopy
(Axioskop X-cite 120, Zeiss, Germany) and the number
of cells that had migrated to the bottom side was
counted.
Western Blots
Animals were sacriﬁced using terminal anaesthesia
and transcardially perfused with 0.9% saline to wash
out all blood. The L5 dorsal horns were rapidly
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spinal segment was cut into a left and right half from
t h ev e n t r a lm i d l i n ea n de a c hh a l fw a sf u r t h e rs p l i t
into the dorsal and ventral horn at the level of the
central canal) and then quickly frozen in liquid nitro-
gen. Microglial cultures or spinal cord dorsal horn
were homogenized in NP40 lysis buffer (20 mM Tris,
pH 8, 137 mM NaCl, 10% glycerol, 1% NP-40, 2 mM
EDTA), 20 lM leupeptin, 5 mM sodium ﬂuoride, 1 mM
sodium orthovanadate, 1 mM PMSF, and protease in-
hibitor cocktail). The lysate were spun at 13,000 rpm
at 4C for 15 min and the protein concentration of su-
pernatant was determined using a BCA Protein Assay
kit (Thermo Scientiﬁc). Proteins (50 lg/tissue lysate,
25 lg/cell lysate) were separated using 8% or 10%
SDS-PAGE, and transferred to nitrocellulose mem-
branes. Membranes were then blocked in 10%
s k i m m e dm i l ki nP B S - T( P B S1 0.1% Tween 20) for 1
hour at room temperature. Membranes were incubated
with primary antibody, rabbit phospho-Akt (1:1,000),
rabbit Akt (1:1,000), rabbit phospho-Erk (1:2,000), rab-
bit Erk (1:2,000), rabbit phospho-p38 (1:500), rabbit
p38 (1:500), diluted in 5% BSA in TBS-T (TBS 1 0.1%
Tween 20, all from Cell Signalling) with gentle shak-
ing at 4C overnight. After washing with PBS-T for
ﬁve times and 5 min each time, membranes were incu-
b a t e dw i t hd o n k e ya n t i - r a b b i tH R P - c o n j u g a t e ds e c o n d -
ary antibody (1:10,000; GE Healthcare) for 1 hour at
room temperature. After several PBS-T washes as
described above membranes were revealed using ECL-
plus reagent (GE Healthcare) for 5 min for detection
by autoradiography.
Quantiﬁcation and Analysis
For immunohistochemistry analysis quantitative
assessment was carried out by determining the numbers
of immunoreactive cells within four areas of 10,000 lm
2
in the superﬁcial dorsal horn on ﬁve to seven randomly
selected L5 spinal sections from each animal. For BrdU
staining the whole dorsal horn was analyzed. Microglia
in which process length was less than double the soma
diameter were classiﬁed as presenting an effector
morphology. Microglia in which the process length was
double the soma diameter were classiﬁed as surveying
(previously called resting) cells (Stence et al., 2001).
Cells were sampled only if the nucleus was visible
within the plane of section and if cells proﬁles exhibited
distinctly delineated borders. All analyses were per-
formed with the operator blinded to treatment groups.
For Western Blots analysis, ﬁlms were scanned with
Cannon Scanner N1240U. Intensity of speciﬁc pERK
and ERK bands (ERK1 44 kDa, and ERK2 42 kDa), as
well as phospho-Akt and Akt (60 kDa) and phospho-p38
and p38MAPK (38 kDa) were quantiﬁed using Adobe
Photoshop 7.0.1. The ratio between phosphorylated
protein and total protein was obtained. This ratio was
normalized against control and expressed as fold
increase.
Statistical Analysis
Sample sizes for experiments were based on results
from pilot studies. Data sets were tested for normality
using the Kolmogorov-Smirnov test and for homogeneity
of variance using Levene’s Test. Parametric or non para-
metric tests were used accordingly. Behavioural data
was analyzed using RM two-way ANOVA. P < 0.05 was
considered as signiﬁcant. Data are presented as mean 6
SEM.
RESULTS
NRG1 Treatment Induced Phosphorylation of
ERK1/2 and Akt Without Activating p38MAPK
To elucidate which intracellular pathways are
involved in NRG1 mediated effects on microglia we
treated primary cultures of microglial cells with NRG1
and investigated a number of key signaling pathways
within these cells. The MAPK pathway is activated by a
number of different growth factors (including NRG1)
and has important roles in cellular proliferation and dif-
ferentiation (Di Segni et al., 2006; Nakaoka et al., 2007;
Neve et al., 2002). We therefore studied two MAPK
pathways: ERK and P38. As shown with Western Blots
resting microglia expressed a very low level of ERK
phosphorylation and no detectable p38MAPK phospho-
rylation in their resting state. On addition of NRG1 10
nM (a dose which in a number of different assays we
have found to be optimum in regulating microglial func-
tion) to microglial cultures phosphorylation of both iso-
forms of ERK (1 and 2) was robustly observed (Fig. 1a,b
control vs. NRG1 60 min ERK1: P 5 0.02, ERK2: P 5
0.003 one-way ANOVA on ranks, n 5 4). By contrast,
p38MAPK was not phosphorylated in response to NRG1
treatment (Fig. 1e). LPS acting via TLR4 has been
shown to activate p38MAPK (Clark et al., 2006;
Lehnardt et al., 2003) and we conﬁrmed this (Fig. 1f).
We also found no potentiation of p38MAPK activation by
NRG1 when cells were primed with LPS (1 lg/mL)
(Fig. 1e–g, LPS vs. LPS 1 NRG1 P 5 0.5, one-way
ANOVA, Bonferroni post hoc test, n 5 3). The PI3K/AKT
pathway has been demonstrated to be activated by
NRG1 in a number of different cell types (Flores et al.,
2000; Fukazawa et al., 2003; Li et al., 2001; Maurel and
Salzer, 2000) and is important for cellular migration,
and in some contexts for survival. This pathway is also
activated in microglia as addition of NRG1 to these cells
led to phosphorylation of Akt (Fig. 1c,d, control vs.
NRG1 60 min, P 5 0.002, one-way ANOVA, Bonferroni
post hoc test).
The MEK/ERK1/2 and PI3K/Akt pathways (but not
p38 MAPK) are therefore downstream of NRG1 signal-
ing in microglial cells. We subsequently explored which
of these pathways were involved in regulating different
aspects of microglial function in response to NRG1. For
this purpose we used two different kinase inhibitors
(Wortmannin which is a speciﬁc covalent inhibitor of
PI3K the kinase upstream of Akt, and U0126 which
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tially determined that these inhibitors had demonstrable
efﬁcacy in selectively blocking these signaling pathways
in microglia. Resting microglial cells were pre-treated
with the different inhibitors for one hour prior to addi-
tion of NRG1 (for 1 further hour) after which we
assessed protein phosphorylation using Western Blots.
Phosphorylation of ERK1 and 2 was selectively blocked
Fig. 1. NRG1 treatment to microglial cells induced phosphorylation
of ERK1/2 and Akt without activating p38MAPK. a and b: Addition of
NRG1 (10 nM) to resting microglial cells induced the phosphorylation
of ERK1/2 as assessed by Western Blots. A representative membrane
for one experiment is shown in a.I nb we show the time-course of
ERK1 (black bars) and ERK2 (grey bars) phosphorylation after NRG1
treatment (ratio of phospho-ERK over total ERK). There was a signiﬁ-
cant increase in ERK1 and 2 phosphorylation after 60 min of NRG1
treatment compared with resting state or control (ERK1: control versus
60 min NRG1 treatment P 5 0.02 one-way ANOVA on ranks, ERK2:
control versus 60 min NRG1 treatment P 5 0.003 one-way ANOVA on
ranks, n 5 4). c and d: In the same way we assessed Akt phosphoryla-
tion after NRG1 treatment. In (c) a representative membrane of one
experiment is shown. In (d) we show the time-course of Akt phosphoryl-
ation (ratio of phospho-Akt over total Akt) after NRG1 treatment of
three independent experiments. There was a signiﬁcant increase in Akt
phosphorylation after 60 min of NRG1 treatment compared with rest-
ing state or control (P 5 0.002, one-way ANOVA, Bonferroni post hoc
test). e and f: NRG1 treatment in microglia did not elicit phosphoryla-
tion of p38MAPK (P 5 0.7, t-test, n 5 3). In e we show the time-course
after NRG1 treatment where no phosphorylation of p38MAPK was
seen. We tested if NRG1 could enhance p38MAPK phosphorylation of
LPS treated microglia but could not observe any increase in phospho-
p38 when treating LPS primed microglia with NRG1. In (f) a repre-
sentative membrane is shown, in (g) we show quantiﬁcation of
phospho-p38 over p38 of 3 independent experiments (NRG1 vs. LPS or
LPS1NRG1 P 5 0.003, LPS vs. LPS1NRG1 P 5 0.5, one-way ANOVA,
Bonferroni post hoc test, n 5 3). In h–j we show that only the MEK in-
hibitor U0126 could block ERK1 and 2 phosphorylation (h) and phos-
phorylation of ERK remained the same when cells were treated with
the PI3K inhibitor Wortmannin (i). Quantiﬁcation of three independent
experiments is shown in j (for ERK 1 and 2 the phospho/total ratio was
signiﬁcantly different between NRG1 treated cells compared with
NRG1 plus U0126 P < 0.05 but not between NRG1 and NRG1 plus
Wortmannin, one-way ANOVA on rank, Dunn’s Method). In k–m we
show that only Wortmannin could block Akt phosphorylation (k) and
U0126 did not affect Akt activation (l). Quantiﬁcation of three inde-
pendent experiments is shown in m (for Akt the phospho/total ratio
was signiﬁcantly different between NRG1 with NRG1 plus Wortmannin
P 5 0.04, but not between NRG1 and NRG1 plus U0126, ANOVA on
Ranks, Dunn’s method) *P < 0.05 Wort 5 Wortmannin. Error bars
represent 6 SEM.
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one-way ANOVA on rank, n 5 3). On the other hand,
phosphorylation of Akt was selectively inhibited by
Wortmannin and not by U0126 (Fig. 1k–m, P 5 0.04,
one-way ANOVA on rank, n 5 3)
The Stimulation of Microglial Proliferation by
NRG1 was Dependant on the MEK/ERK1/2
Pathway
We previously showed that NRG1 is a potent prolifer-
ative factor to microglia (Calvo et al., 2010). To explore
which intracellular pathway was involved in this pro-
mitotic effect we used the inhibitors described above.
Microglial cells were cultured in medium supplemented
with 5% FBS and cell proliferation in response to NRG1,
with and without the kinase inhibitors was quantiﬁed
using pulse labelling with BrdU. NRG1 treatment
increased the proliferation of microglia from 14% (base-
line levels) to 51%. This effect was dependent on phos-
phorylation of ERK1/2 as it could be inhibited by the
MEK inhibitor U0126 but not by the PI3K inhibitor
Wortmannin (Fig. 2, NRG1 treatment alone compared
with NRG1 plus U0126 P < 0.001, NRG1 vs. NRG1 plus
Wortmannin P 5 0.54, one-way ANOVA, Bonferroni post
hoc test, n 5 3–4).
The Survival Effect of NRG1 in Microglia was
Dependant on ERK1/2 and Akt Activation
NRG1 can promote survival of microglia when these
cells were left in serum free medium (a condition that
normally provokes apoptotic cell death). After 72 hours
of incubation in the absence of serum we assessed micro-
glial numbers in the presence of NRG1 and the different
kinase inhibitors. As previously shown NRG1 promoted
microglial survival (see Fig. 3) and this effect could be
blocked by adding the PI3K inhibitor Wortmannin and
to a lesser extent the MEK inhibitor U0126 (NRG1 vs.
NRG1 plus Wortmannin P < 0.001, NRG1 vs. NRG1
plus U0126 P 5 0.01, one-way ANOVA, Bonferroni post
hoc test, n 5 4–5). This indicates that the PI3K/Akt and
the MEK/ERK1/2 pathways are responsible for the sur-
vival-promoting effects of NRG1.
The Chemotactic Effect of NRG1 in Microglia
was Dependant on Akt Activation
Microglial cells can migrate through the CNS towards
a site of injury and indeed NRG1 can act as a chemotac-
tic factor for microglia. Using a Boyden chamber in
which microglia migrate through pores in a polycarbon-
ate ﬁlter across a concentration gradient we tested which
intracellular signaling pathways are involved in the
chemo-attractant effect of NRG1. Pre-incubating micro-
glia for one hour with Wortmannin before adding the
cells to the Boyden chamber with a NRG1 gradient could
completely block the chemoattractive effect of NRG1
(Fig. 4, NRG1 vs. NRG1 plus Wortmannin P <0.001,
one-way ANOVA, Bonferroni post hoc). Preincubation
with U0126 had no effect (P 5 0.8) suggesting that
PI3K/Akt and not MEK/ERK1/2 pathway is involved in
generating the chemotactic response to NRG1.
Intrathecal NRG1-Induced Sustained ERK1/2
Phosphorylation but Transient Akt Activation
in Spinal Microglia of Naive Animals
To investigate the intracellular signaling involved
in mediating NRG1 effects on microglia in vivo we
administered this molecule intrathecally (0.4 or 4 ng
administered daily for 4 days) to naive animals and
used immunohistochemistry and western blot analysis
Fig. 2. NRG1 effect on microglial proliferation was dependant on
MEK/ERK1/2 pathway. Proliferation was assessed by incubating micro-
glia in medium supplemented with 5% FBS for 3 days and pulse-label-
ing for 16 hours with BrdU 10 lM. Microglia, were ﬁxed and stained
(Iba1 to label microglial cells in red, DAPI to label nuclei in blue, and
BrdU to label proliferating nuclei in yellow). NRG1 10 nM treatment
signiﬁcantly increased the proportion of BrdU-positive microglial nuclei
compared with control (a and b). This effect of NRG1 was signiﬁcantly
inhibited when cells were treated with the MEK inhibitor U0126 (d)
but not when cells were treated with the PI3K inhibitor Wortmannin
(c). In (e) we show quantiﬁcation of four independent experiments.
(NRG1 treatment compared with NRG1 plus U0126 P < 0.001, NRG1
compared with NRG1 plus Wortmannin P 5 0.547, one-way ANOVA,
Bonferroni post hoc test). Note that both inhibitors by their own did not
change baseline levels of proliferation. Wort 5 Wortmannin. Scale bar:
50 lm. Error bars represent 6 SEM.
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GLIAto identify the intracellular pathways activated. We
observed no associated morbidity with the repeated i.t.
injections (there was no change in general well being or
body weight of the animals in all groups; animals from
the saline group presented unchanged mechanical and
cold sensitivity throughout the study). At 4 days after
repeated NRG1 injections this molecule induced an
increase in microglial numbers in the dorsal horn and
these cells expressed the phosphorylated form of ERK1/
2. Very few microglia in the dorsal horn of control
animals presented phospho-ERK immunoreactivity
(approximately 10%) compared with NRG1 (4 ng)
treated animals in which 45% of dorsal horn microglial
were phospho-ERK positive (Fig. 5a–g, control vs. NRG1
4n gP < 0.05, one-way ANOVA on ranks). We conﬁrmed
these results by performing Western blots analysis
which showed a signiﬁcant increase in ERK1/2 phospho-
rylation within the spinal dorsal horn of animals treated
with NRG1 (4 ng) compared with control (Fig. 5h,i,
control vs. NRG1 ERK1 P 5 0.02, ERK2 P < 0.001,
t-test, n 5 4 per group).
We also studied the p38MAPK and PI3K/Akt path-
ways. Following 4 days of repeated intrathecal treatment
with 4 ng NRG1 (a dose which leads to increased micro-
glial numbers and pain related behaviour see below) we
found very scarce phospho-p38 immunoreactivity in
microglia which was not signiﬁcantly different from con-
trol (P 5 0.6, Mann-Whitney Rank Sum Test, n 5 4 per
group, Supp. Info. Fig. 1a–g). The Western blot analysis
of the spinal cord of these animals showed no change
in p38MAPK phosphorylation after NRG1 treatment
(P 5 0.6, t-test, n 5 4 per group, Supp. Info. Fig. 1h,i).
Similarly, at four days (96 hours) after repeated NRG1
injections very few microglia presented phospho-Akt
immunoreactivity which was not signiﬁcantly different
from control (Supp. Info. Fig. 2). This was conﬁrmed by
Fig. 4. NRG1 effect on microglial chemotaxis was dependant on
PI3K/Akt pathway. The effects of NRG1 on microglial migration were
studied using a Boyden chamber. The addition of NRG1 to the lower
well of the chamber (b) increased microglial migration to the inner
membrane surface compared with control (a) This effect of NRG1 was
signiﬁcantly inhibited when cells were pretreated for 1 hour with the
PI3K inhibitor Wortmannin (c) but not when cells were pretreated with
the MEK inhibitor U0126 (d). In e we show quantiﬁcation of four
independent experiments. (NRG1 treatment compared with NRG1 plus
Wortmannin P < 0.001, NRG1 treatment compared with NRG1 plus
U0126 P 5 0.8, one-way ANOVA, Bonferroni post hoc test). Note
that both inhibitors by their own did not change baseline levels of che-
motaxis. Wort 5 Wortmannin. Scale bar: 100 lm. Error bars represent
6 SEM. [Color ﬁgure can be viewed in the online issue, which is avail-
able at wileyonlinelibrary.com.]
Fig. 3. NRG1 effect on microglial survival was dependant on PI3K/
Akt and MEK/ERK pathways. Microglial survival was assessed by incu-
bating the cells in ‘‘starving conditions’’ (i.e. medium without FBS) for
3 days. Microglia, were ﬁxed and stained (Iba1 to label microglial cells
in red and DAPI to label nuclei in blue). NRG1 10 nM treatment
signiﬁcantly increased the number of cells per well compared with con-
trol (a and b). This effect of NRG1 was signiﬁcantly inhibited when
cells were treated with the PI3K inhibitor Wortmannin (c) and with
the MEK inhibitor U0126 (d). In (e) we show quantiﬁcation of ﬁve inde-
pendent experiments. (NRG1 vs. NRG1 1 Wortmannin P < 0.001,
NRG1 vs. NRG1 1 U0126 P 5 0.01, one-way ANOVA, Bonferroni post
hoc test). Note that both inhibitors by their own did not change base-
line levels of survival. Wort 5 Wortmannin. Scale bar: 100 lm. Error
bars represent 6 SEM. [Color ﬁgure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
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phosphorylation (P 5 0.5, t-test, n 5 4 per group, Supp.
Info. Fig. 2h,i). As we had previously found that the
PI3K/Akt pathway is activated by NRG1 in microglial
cells in vitro we further investigated the involvement of
this pathway at an earlier time points after NRG1 injec-
tion in vivo. We found a transient and small activation
of this pathway which peaked at 6 hours after NRG1
injections and then returned to control (there was a sig-
niﬁcant increase in the percentage of microglia that
were phospho-Akt positive; from 0.24% in control to
2.71% in NRG1 6 hours, P < 0.001, one-way ANOVA,
Bonferroni post hoc test, n 5 4, Supp. Info. Fig. 2a–g).
Therefore the key signaling pathway activated within
microglia following NRG1 treatment in vivo is the MEK/
ERK pathway and we subsequently focused on this.
Inhibition of MEK1/2 Could Reverse NRG1-
Induced Microgliosis and Mechanical and Cold
Pain-Related Hypersensitivity
We next tested the hypothesis that MEK/ERK1/2
pathway was necessary for NRG1 signaling in vivo. For
this purpose we intrathecally administered the MEK
inhibitor U0126 (10 lg) or its inactive analogue U0124
(10 lg) at the same time as NRG1 (4 ng). We repeated
the i.t injection every 24 hours for 4 days. Animals
underwent behavioural testing every day for 3 days and
were perfused at day 4. NRG1 injections elicited micro-
gliosis in the lumbar spinal cord. Animals injected with
NRG1 plus the inactive analogue U0124 showed an
increase in microglial numbers, increased proliferation
of these cells (as shown with BrdU labeling) and in addi-
tion the morphology of these cells changed with cellular
hypertrophy and process retraction. We found that the
NRG1 induced microgliosis was dependant on the MEK/
ERK1/2 pathway as inhibiting ERK1/2 phosphorylation
by MEK (using U0126) could prevent microgliosis
(Fig. 6a–l). When NRG1 was injected with the inactive
analogue U0124 there was a signiﬁcant increase in the
number of microglia with an effector morphology (P <
0.001) and which were BrdU labeled (P 5 0.001) com-
pared with saline injections. These effects were virtually
completely blocked when NRG1 was injected together
with the MEK inhibitor U0126 which resulted in no sig-
niﬁcant difference from the saline group. We used one-
way Analysis of Variance on Ranks in both comparisons.
Intrathecal NRG1 is pronociceptive and in these animals
it elicited mechanical and cold pain related hypersensi-
tivity. The MEK inhibitor U0126 could completely
prevent NRG1 induced mechanical hypersensitivity
Fig. 5. Intrathecal administration of NRG1 for 4 consecutive days
induced ERK1/2 phosphorylation in spinal microglia of naive animals.
Representative sections are shown of control (saline in a–c) and NRG1
(in d–f) immunostained with an antibody that recognises the phospho-
rylated form of ERK1/2 (green) and Iba1 (red). In (g) we show quantiﬁ-
cation of the percentage of microglia (Iba1 positive cells) that were
phospho-ERK positive. A signiﬁcant increase in microglia presenting
phospho-ERK was found when comparing control vs. NRG1 4 ng (P <
0.05, one-way ANOVA on ranks). We conﬁrmed these results using WB.
Phosphorylation of ERK 1 and 2 was signiﬁcantly increased after
NRG1 intrathecal injections (h). In (i) we showed the quantiﬁcation of
the ratio of phosphorylated to total ERK 1 and 2 (control vs. NRG1
ERK1 P 5 0.02, ERK2 P < 0.001, t-test, n 5 4 per group) **P < 0.001;
*P < 0.05. Scale bar: 50 lm. Error bars represent 6 SEM.
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cantly different between NRG1 1 U0124 vs. NRG1 1
U0126 at day 2 and day 3 (both P < 0.001). Cold hyper-
sensitivity was also signiﬁcantly different between these
groups at day 2 (P 5 0.004) and day 3 (P < 0.001) (for
both comparisons we used RM two-way ANOVA Bonfer-
roni post hoc, n 5 8 per group).
Blocking NRG1/erbB2 Signaling After L5 Spinal
Nerve Ligation Reduced ERK1/2 Phosphorylation
in Spinal Cord Microglia
We next studied whether the ERK pathway is down-
stream of NRG1-erbB signaling in a nerve injury model
which results in a robust microgliosis [L5 spinal nerve
ligation (Kim and Chung, 1992)]. As previously shown
by others (Zhuang et al., 2005) we found that the pro-
portion of microglia which expressed phospho-ERK
increased from a naive level of around 8% to 45% 3 days
after such injury. To test if the erbB receptor kinases
activated by NRG1 were upstream of ERK phosphoryla-
tion we administered the speciﬁc erbB receptor blocker
PD168393 [which blocks the ATP binding site of the re-
ceptor (Bose et al., 2006) and we have previously found
effective in inhibiting NRG1 signaling in vivo (Calvo
et al., 2010)] via a continuous intrathecal infusion fol-
lowing spinal nerve ligation. At day 3 after spinal nerve
ligation, when the microglial response is well estab-
lished, we found that the erbB receptor inhibitor
PD168393 dramatically reduced the percentage of phos-
pho-ERK immunoreactive microglia in the ipsilateral
dorsal horn from approximately 45% in vehicle to 20%
in erbB inhibitor infused animals (Fig. 7a–g, P < 0.001
t-test, n 5 4 per group). PD168393 will not only block
NRG1 signaling but through inhibition of erbB1 may
Fig. 6. Inhibition of MEK1/2 could reverse NRG1-induced microglio-
sis and mechanical and cold pain-related hypersensitivity. NRG1 was
administered intrathecally (4 ng given daily for 3 days) together with
the MEK inhibitor U0126 (10 lg) or the inactive analogue U0124
(10 lg). a and b: Dorsal horn of animals treated with NRG1 1 U0124
(in a) or NRG1 1 U0126 (in b) immunostained with Iba1. Note that
U0126 but not U0124 could prevent NRG1 associated increase in num-
bers of microglia with an effector morphology. In c quantiﬁcation of
this response is shown. In d–k we assessed proliferation (pulse labeling
with BrdU) after injections (Iba1 is shown in red, DAPI in blue, BrdU
in yellow and in the last panel merged images are shown). d–g: Dorsal
horn microglia from a NRG1 1 U0124 treated animal. h–k: Dorsal
horn microglia from a NRG1 1 U0126 treated animal. In (l) quantiﬁca-
tion of all BrdU-positive microglia in the dorsal horn is shown. Again,
U0126 but not U0124 prevented NRG1 induced increase in microglial
proliferation. Mechanical (shown in m) and cold (shown in n) pain
related hypersensitivity developed after NRG1 injections which were
reversed by U0126 but not by U0124. Scale bars: a and b: 100 lm, d–k:
50 lm. *P <0.05, **P < 0.001. Error bars represent 6 SEM.
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alternative strategy was also employed to block NRG1-
erbB signaling. We used a molecule (HBD-S-H4) to
sequester endogenous NRG1. This is a fusion protein
consisting of the soluble ectodomain of erbB4, which has
high afﬁnity for NRG1, and a heparin-binding domain,
which helps target the molecule to the same heparan-
sulfate rich cell surfaces that bind NRG1. This molecule
has previously been shown to be highly effective in vitro
and in vivo (Calvo et al., 2010; Ma et al., 2009). Intra-
thecal administration of HBD-S-H4 (3 lg, i.t. injection)
signiﬁcantly reduced the percentage of phospho-ERK
immunopositive microglia (form approximately 44%
in control to 19% in NRG1 antagonist treated animals,
P 5 0.006, t-test, n 5 4, Fig. 7g).
To conﬁrm these results we performed Western blots
analysis to detect the ratio of phosphorylated to total
ERK 1 and 2 in the dorsal horn of PD168393 versus ve-
hicle treated animals 3 days after spinal nerve ligation.
The phosphorylation of ERK 1 and 2 presented a twofold
Fig. 7. Blocking NRG1-erbB signaling after L5 SNL reduced ERK1/
2 phosphorylation in spinal cord microglia. Using immunohistochemis-
try (Iba1 in red, phospho-ERK in green) we observed that ERK was
phosphorylated in spinal microglia following SNL. In a–c, a representa-
tive section of the ipsilateral dorsal horn of a vehicle treated animal is
shown. In d–f, a representative section of an animal treated with
PD168393 (erbB receptor inhibitor) is shown. Note the reduction of
phospho-ERK positive microglia when this inhibitor is administered.
We also used a NRG1 sequestering molecule (HBD-S-H4) that was
injected intrathecally following L5 SNL and found similar results. In
(g) we show the quantiﬁcation of the percentages of phospho-ERK posi-
tive microglia in both experiments (vehicle vs. erbB inhibitor P <
0.001, t-test, n 5 4; control vs. NRG1 antagonist P 5 0.006, t-test, n 5
4). To conﬁrm these results we used WB analysis of the ipsilateral dor-
sal horn of animals treated with the erbB inhibitor. A representative
blot is shown in (h) in where an increase in phosphorylated ERK1/2 is
seen after nerve injury which was greatly decreased when using the
erbB receptor inhibitor. In (i) we show quantiﬁcation of the WB of four
animals per group (vehicle vs. inhibitor: ERK1 and 2 P 5 0.04, one-way
ANOVA on ranks, Bonferroni post hoc)* P < 0.05, **P < 0.001. Scale
bar: 50 lm. Error bars represent 6 SEM. VEH: vehicle, INH: erbB2
inhibitor (PD168393), ANT: HBD-S-H4.
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reversed by treatment with PD168393 (Fig. 7h,i, vehicle
vs. inhibitor: ERK1 and 2 P 5 0.04, one-way ANOVA on
ranks, Bonferroni post hoc, n 5 4 per group).
Interestingly we have previously found that disrupt-
ing the NRG1-erbB signaling pathway after SNL could
reduce the total number of microglial cells expressing
the phosphorylated form of p38MAPK (Calvo et al.,
2010). This seems at odds with the fact that we could
not ﬁnd activation of p38 MAPK by NRG1 either in vitro
or in vivo. When we further analyzed this data however
we have found that the percentage of microglia express-
ing phospho-p38MAPK did not change with erbB inhibi-
tion. In sham animals 29% of microglia were phospho-
p38MAPK immunoreactive, this percentage increased
after peripheral nerve injury to 83% (vehicle animals)
and remained the same with erbB inhibition (74%, P 5
0.27, one-way ANOVA, Bonferroni post hoc test, n 5
3–5). The reduction in total pp38 immunoreactive
microglia following erbB inhibition is likely to reﬂect a
reduction in the number of microglia within the dorsal
horn rather than a direct modulation of this pathway
by NRG1.
Microglial Proliferation After L5 Spinal Nerve
Ligation was Decreased by Blocking MEK1/2
Pathways
We have previously shown that NRG1-erbB signaling
induces microglial proliferation after spinal nerve liga-
tion. To test wherever this in vivo effect was dependant
on MEK/ERK1/2 pathways we administered the MEK
inhibitor U0126 or its inactive analogue U0124 intrathe-
cally via repeated lumbar punctures following nerve
injury. We pulse labeled the animals with BrdU to
assess cell proliferation. Microgliosis was dramatically
reduced by the MEK inhibitor (Fig. 8, P < 0.001 compar-
Fig. 8. Microgliosis and mechanical and cold hypersensitivity follow-
ing L5 SNL were signiﬁcantly reduced by blocking MEK1/2 pathways.
Animals underwent L5 SNL and were injected intrathecally daily with
a1 0lg dose of the MEK inhibitor U0126 or its inactive analogue
U0124. Three days after SNL animals treated with the inactive ana-
logue U0124 demonstrated a dramatic increase in the number of dorsal
horn microglia showing an effector morphology compared with na€ ıve
animals injected with saline. This microgliosis was signiﬁcantly
reduced when animals received the MEK inhibitor U0126. In (a) (SNL
1 U0124) and (b) (SNL 1 U0126) we show representative sections of
the L5 spinal cord of these animals stained with Iba1 to label microglia.
In (c) we show the quantiﬁcation (n 5 4 per group, P < 0.001 SNL 1
U0124 vs. SNL 1 U0126, one-way ANOVA, Bonferroni post hoc test).
Similarly, increased microglial proliferation was found in SNL animals
that were treated with the inactive MEK inhibitor and it was greatly
reduced (by more than 70%) in animals treated with U0126. In d–k,w e
show representative section of L5 spinal cord immunostained for Iba1
(red), BrdU (yellow), and DAPI (blue). Panels d–g show an inactive
analogue (U0124) treated animal and panels h–k show a MEK inhibitor
treated animal, both 3 days after L5 SNL. Quantiﬁcation of BrdU-posi-
tive nuclei in the dorsal horn is shown in (l)( n 5 4 per group, P <
0.001 SNL 1 U0124 vs. SNL 1 U0126, one-way ANOVA, Bonferroni
post hoc test). Mechanical (shown in m) and cold (shown in n) pain
related hypersensitivity developed after L5 SNL which were partially
prevented by U0126 but not by U0124 (**P < 0.001, *P < 0.05, RM
two-way ANOVA, Bonferroni post hoc test, n 5 7–8 for m and n). Scale
bars, a and b 100 lm, c–j 25 lm.
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GLIAing SNL 1 U0124 vs. SNL 1 U0126, one-way ANOVA,
Bonferroni post hoc, n 5 4 per group). The time point of 3
days postinjury was used because microglial proliferation
is maximal at this time (Echeverry et al., 2008) and thus
we found a marked increase in the rate of microglial pro-
liferation within the dorsal horn of the spinal cord. Inter-
estingly we observed that blocking MEK with U0126
could reduce microglial proliferation horn by 73% (Fig. 8,
P < 0.001 comparing SNL 1 U0124 vs. SNL 1 U0126,
one-way ANOVA, Bonferroni post hoc, n 5 4p e rg r o u p )
Inhibition of MEK1/2 Reduced the Mechanical and
Cold Pain-Related Hypersensitivity Following
Peripheral Nerve Injury
Inhibition of the MEK/ERK pathway has been shown
previously to reduce mechanical hypersensitivity after
spinal nerve ligation (Obata et al., 2004; Zhuang et al.,
2005). We tested if inhibiting this pathway, which could
reduce microglial proliferation, would also reduce
mechanical and cold pain related hypersensitivity after
nerve injury. Rats underwent L5 SNL and received daily
intrathecal injections with the MEK inhibitor U0126 or
the inactive analogue U0124. Animals receiving U0124
developed mechanical and cold hypersensitivity. The
MEK inhibitor could partially prevent mechanical
hypersensitivity (Fig. 8m, P < 0.001 at day 2, P 5 0.001
at day 3, P 5 0.01 at day 5, and P 5 0.002 at day 7).
Cold hypersensitivity was also signiﬁcantly different
between these groups at day 5 (P 5 0.03) and day 7
(P < 0.001) (for both comparisons we used RM two-way
ANOVA Bonferroni post hoc, n 5 7–8 per group).
DISCUSSION
NRG1 has recently been identiﬁed as a pro-nociceptive
growth factor which is expressed by primary afferents,
released within the dorsal horn following nerve injury
and which promotes microgliosis and hence the develop-
ment of neuropathic pain. Here we show that NRG1
activates both the MEK/ERK and PI3K/AKT pathways
in microglia in vitro. The former modulates proliferation
and the latter chemotaxis of cultured microglia, both
appear to have a role in survival. Intrathecal treatment
with NRG1 in vivo produced activation of the MEK/ERK
pathway and this was critical for the development of
microglial proliferation and pain related behaviour.
Following nerve injury ERK was activated within micro-
glia downstream of NRG1-erbB signaling and this drives
microglial proliferation and the development of neuro-
pathic pain.
Microglia and Neuropathic Pain: The
Role of NRG1
Peripheral nerve injury results in a dramatic increase
in the number of microglia within the spinal cord
through proliferation and migration of resident cells
(Ajami et al., 2007; Echeverry et al., 2008; Raivich et al.,
1994). Microglia have receptors for and respond to
injury signals such as cytokines and chemokines (e.g.
CCL2, Fractalkine, and IFN-g), complement components
and purines (Clark et al., 2007; Grifﬁn et al., 2007;
Tanga et al., 2005; Tsuda et al., 2003, 2009; Thacker
et al., 2009; Verge et al., 2004; Zhang et al., 2007).
Microglia switch into a proinﬂammatory phenotype
secreting cytokines, nitric oxide and BDNF which
enhance the excitability of dorsal horn neurons (Coull
et al., 2005; Kawasaki et al., 2008). Microgliosis at the
level of the brainstem can contribute to enhanced
descending pain facilitation following nerve injury (Wei
et al., 2008). This excessive pro-inﬂammatory microglial
response to which NRG1 contributes is clearly deleteri-
ous as it promotes the development and maintenance of
neuropathic pain (Calvo et al., 2010; Clark et al., 2007;
Coull et al., 2005; Ledeboer et al., 2005; Tsuda et al.,
2003; reviewed in Ren and Dubner, 2008).
ErbB receptor activation by NRG1 results in the stim-
ulation of a number of intracellular signaling pathways
including the PI3K/AKT, MEK/ERK, and p38MAPK
pathways (Di Segni et al., 2006;Liu et al., 1999; Nakaoka
et al., 2007) resulting in the induction of a variety of
cellular responses including proliferation, migration, dif-
ferentiation, survival or apoptosis (reviewed in Britsch,
2007). Our initial approach in investigating intracellular
signaling pathways activated by NRG1 in microglia was
to study the actions of this molecule on primary cultures
of these cells and subsequently investigate their role in
mediating the effects of NRG1 in vivo.
The PI3K-AKT Pathway Mediates the
Microglial Survival and Chemotactic
Effects of NRG1 In Vitro
Akt is a downstream effector of phosphoinositide 3-
kinases (PI3Ks); it has been shown to be activated in
response to NRG1-erbB signaling and to increase sur-
vival in a variety of different cell types (Flores et al.,
2000; Fukazawa et al., 2003; Li et al., 2001; Maurel and
Salzer, 2000). Within microglia and macrophages the
PI3K/AKT pathway promotes survival and regulates cell
polarity, which is necessary for cell motility and direc-
tional sensing in the process of chemotaxis for instance
to ATP (Adapala et al., 2010; Hirsch et al., 2000;
Horvath and DeLeo, 2009; Irino et al., 2008; Ohsawa
et al., 2007; Ruan et al., 2010; Weiss-Haljiti et al., 2004).
NRG1 treatment of cultured microglial cells signiﬁ-
cantly increased phosphorylation of Akt. Selective inhi-
bition of PI3K virtually abolished the survival and the
chemotactic effects of NRG1 on cultured microglia. In
contrast to the ﬁndings in cultured microglia we only
found transient activation of PI3K/AKT in a very small
population of microglia following intrathecal treatment
with NRG1 in vivo in a manner that did not correlate
with pain related behaviour. Importantly this was at a
dose of NRG1 which produces both microgliosis, and
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theoretically possible that a higher dose of NRG1 may
have activated PI3K/Akt however the physiological rele-
vance would have been unclear. One potential reason for
these differences is the different cellular context of
microglia in primary cultures versus whole spinal cord.
However in accordance with previous reports we did
observe an increase in phospho-Akt immunoreactivity
within the dorsal horn at 3 days after peripheral nerve
injury (Xu et al., 2007) but most of the cells expressing
it were not microglia (unpublished observations). Inhibi-
tion of this pathway has been shown to reduce pain
related hypersensitivity (Xu et al., 2007) and therefore
PI3K/Akt pathway seems to play a role in regulating
neuronal plasticity in vivo but it is not a key mediator of
NRG1 action on microglia.
Activation of the MEK/ERK Pathway by NRG1
Promotes Microglial Proliferation and the
Development of Neuropathic Pain
Mitogen-activated kinases (MAPKs) are a family of
well conserved molecules critical in intracellular signal
transduction with important roles in regulating neural
plasticity and the inﬂammatory response. They include
three major members: extracellular signal-regulated
kinase (ERK1/2 or p42/44 MAPK), p38, and c-Jun N-
terminal kinase (JNK). Following peripheral nerve
injury p38MAPK and ERK have been shown to be acti-
vated in spinal microglia and JNK is activated in astro-
cytes (reviewed in Ji et al., 2009).
P38 MAPK, is regarded as a stress-induced kinase as
it plays a critical role in inﬂammatory responses
(reviewed in Ji and Suter, 2007). It is important for the
synthesis of several pro-inﬂammatory mediators by
microglia such as cyclooxygenase-2, IL-1b, BDNF; and
iNOS (Clark et al., 2006; Coull et al., 2005; Sung et al.,
2005; Svensson et al., 2003; Trang et al., 2009). Follow-
ing nerve injury P38 MAPK activation contributes to
neuropathic pain development/maintenance (Jin et al.,
2003; Tsuda et al., 2004). We did not however ﬁnd
evidence of activation of p38 MAPK by NRG1 either in
cultured microglia or following intrathecal treatment
in vivo. We have previously shown that inhibition of
NRG1-erbB signaling following SNL reduces the number
of microglia within the dorsal horn of the spinal cord
and the total number of phospho-p38 immunoreactive
microglia. However the proportion of microglia express-
ing phospho-p38 MAPK did not change with inhibition
of the NRG1-erbB signaling. The decrease in the total
number of phospho-p38 MAPK positive microglia follow-
ing NRG1-erbB signaling disruption is therefore not a
direct effect of NRG1 but may be due to the fact that
NRG1 is required for the early proliferative response of
these cells (see below).
ERK exists in two isoforms (1 and 2) which are acti-
vated by upstream kinase MEK1/2 (MKK1/2) and has
been implicated in regulating the proliferation, differen-
tiation, and survival of cells during development
(reviewed in Widmann et al., 1999). ERK activation has
been shown to be essential for the proliferative actions
of a number of growth factors such as GM-CSF on
microglia (Suh et al., 2005). ERK also mediates the
release of a number of pro-inﬂammatory mediators such
as TNF-a and NO from cultured microglial cells (Bhat
et al., 1998; Hide et al., 2000; Romero-Sandoval et al.,
2009; Tichauer et al., 2007). In spinal cord injury models
MEK/ERK inhibition dramatically reduced microglial
accumulation, IL-1b expression and the spinal release of
prostaglandin E2 (Lu et al., 2007; Zhao et al., 2006,
2007). Following peripheral nerve injury ERK is acti-
vated acutely within hours in dorsal horn neurons, from
day 2 postinjury in microglia and then more chronically
from day 10 onwards in astrocytes (Zhuang et al., 2005).
ERK signaling is also activated within microglia in the
Streptozotocin induced model of diabetic neuropathy
(Tsuda et al., 2008). Inhibition of the MEK/ERK path-
way can reduce mechanical pain related hypersensitivity
in these different models of nerve injury. Following
peripheral axotomy the Src-family kinases (SFKs) are
activated in spinal microglia upstream of ERK and con-
tribute to the development of mechanical hypersensitiv-
ity (Katsura et al., 2006). This is interesting as it has
been shown that the erbB signaling requires the engage-
ment of Src kinases to trigger MAPK activation
(Olayioye et al., 2001).
NRG1 produced phosphorylation of ERK1 and 2 in
cultured microglial cells. Inhibition of this pathway pre-
vented NRG1 induced proliferation in vitro. Intrathecal
treatment with NRG1 in na€ ıve animals induced ERK1/2
phosphorylation within spinal cord microglia. This was
associated with microglial proliferation, adoption of an
effector morphology, and development of cold and
mechanical pain related hypersensitivity. These changes
could be virtually completely reversed by MEK inhibi-
tion. Spinal nerve ligation provides a well-characterized
model of nerve injury associated with a robust microglio-
sis (Scholz and Woolf, 2007; Tsuda et al., 2003) and
development of neuropathic pain (Kim and Chung,
1992). SNL results in increased NRG1 release within
the spinal cord dorsal horn (Calvo et al., 2010) and CSF
(Calvo et al., unpublished observations) resulting in acti-
vation of the erbB2 receptor speciﬁcally within microglia
(Calvo et al., 2010). We have found that activation of
NRG1-erbB signaling in these cells following axotomy is
accompanied by extensive ERK 1/2 phosphorylation.
This activation of ERK signaling is downstream of the
erbB receptors as receptor inhibition or sequestration of
endogenous NRG1 resulted in a signiﬁcant reduction in
ERK1/2 phosphorylation. Inhibition of the MEK/ERK1/2
pathway following SNL reduced both microglial prolifer-
ation as well as mechanical and cold pain related hyper-
sensitivity. ERK inhibition has also been shown to
reduce established neuropathic pain related behavior
within 3 hours of intrathecal injection (Zhuang et al.,
2005). This rapid response would indicate that the
effects of ERK inhibition are not solely related to a
reduction in microglial proliferation but will also include
actions such as reduced cytokine release (Zhao et al.,
566 CALVO ET AL.
GLIA2007). In summary although both ERK and p38 have
been shown to be activated in microglia following nerve
injury only the former is directly stimulated by NRG1
signaling. There is some evidence that these signaling
pathways may be activated differentially among the
microglial population (Katsura et al., 2006).
CONCLUSIONS
We conclude that peripheral nerve injury results in
the release of NRG1 within the dorsal horn of the spinal
cord and activation of erbB receptors on microglia. This
stimulates the MEK/ERK1/2 pathway which plays a
pivotal role in the microglial mitotic response and con-
tributes to the development of neuropathic pain. This
pathway offers a potential target to modulate microglio-
sis and may also be relevant to other forms of injury to
the nervous system.
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